A phase I/II open-label trial (NCT04965818) is being conducted to assess the safety and preliminary efficacy of futibatinib and binimetinib (MEK inhibitor) in patients with advanced NSCLC with KRAS mutation [111]. Here, MAP2K7 is linked to non-small cell lung carcinoma.